HC Wainwright Has Bearish Estimate for Innoviva Q1 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Analysts at HC Wainwright decreased their Q1 2026 earnings estimates for shares of Innoviva in a research note issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of $0.42 per share for the quarter, down from their previous forecast of $0.45. HC Wainwright currently has a “Buy” rating and a $46.00 price target on the stock. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Innoviva’s Q2 2026 earnings at $0.51 EPS, Q3 2026 earnings at $0.48 EPS, Q4 2026 earnings at $0.55 EPS, FY2026 earnings at $1.96 EPS, Q1 2027 earnings at $0.53 EPS, Q2 2027 earnings at $0.65 EPS, Q3 2027 earnings at $0.63 EPS and Q4 2027 earnings at $0.69 EPS.

Other research analysts also recently issued reports about the company. BTIG Research restated a “buy” rating and set a $35.00 target price on shares of Innoviva in a research note on Thursday, February 26th. Cantor Fitzgerald increased their price target on Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Zacks Research lowered Innoviva from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Innoviva in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.17.

Innoviva Stock Performance

Shares of INVA stock opened at $22.30 on Wednesday. Innoviva has a 12-month low of $16.52 and a 12-month high of $25.15. The business’s fifty day simple moving average is $20.98 and its 200-day simple moving average is $20.10. The company has a current ratio of 14.64, a quick ratio of 13.85 and a debt-to-equity ratio of 0.22. The company has a market cap of $1.67 billion, a PE ratio of 7.31 and a beta of 0.42.

Innoviva (NASDAQ:INVA) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $1.94 earnings per share for the quarter, beating the consensus estimate of $0.34 by $1.60. Innoviva had a net margin of 65.92% and a return on equity of 37.63%. The company had revenue of $114.61 million during the quarter, compared to the consensus estimate of $102.62 million.

Institutional Trading of Innoviva

Several large investors have recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new position in shares of Innoviva in the second quarter worth about $43,000. EverSource Wealth Advisors LLC boosted its position in Innoviva by 297.7% in the second quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,795 shares during the last quarter. Danske Bank A S acquired a new position in Innoviva in the 3rd quarter worth approximately $55,000. Asset Management One Co. Ltd. purchased a new position in Innoviva during the 3rd quarter worth approximately $60,000. Finally, Toth Financial Advisory Corp purchased a new position in Innoviva during the 3rd quarter worth approximately $63,000. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Trending Headlines about Innoviva

Here are the key news stories impacting Innoviva this week:

• Positive Sentiment: HC Wainwright kept a strong stance on INVA with a “Buy” rating and a lofty $46.00 price target, and published multi-year EPS projections that imply substantial upside in 2026–2027 (their FY2026 and 2027 quarterly forecasts are materially higher than the Street consensus). This bullish posture supports upside sentiment and is a key reason investors may be bidding the stock higher today.
• Positive Sentiment: Cantor Fitzgerald raised its price target on INVA to $32 from $31, signaling incremental analyst optimism and adding to positive momentum. Cantor Fitzgerald Lifts PT
• Neutral Sentiment: Sector/peer disruption: news that Theravance Biopharma’s Phase 3 trial failed and the company is restructuring is moving respiratory/biotech headlines; impact on Innoviva is indirect unless investors re‑price royalty/partner exposures—this is a watch item but not a direct company announcement. Theravance Biopharma Plummets Theravance Restructures
• Negative Sentiment: HC Wainwright trimmed several near‑term EPS forecasts for INVA (Q1–Q4 2026 quarter-by-quarter cuts and a FY2026 reduction from $2.23 to $1.96). Specific downgrades included Q1 2026 (from $0.45 to $0.42), Q2 2026 (from $0.56 to $0.51), Q3 2026 (from $0.57 to $0.48) and Q4 2026 (from $0.66 to $0.55). Those downward revisions are a negative signal for near-term earnings momentum and could cap upside despite the high price targets.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.